23andMe, MyoKardia to Create Hypertrophic Cardiomyopathy Patient Community

Oct 25, 2018

|

NEW YORK (GenomeWeb) – MyoKardia said today that it is collaborating with 23andMe to create a patient community to advance research into hypertrophic cardiomyopathy (HCM), a progressive and frequently debilitating disease characterized by excessive contractility of the heart.

Under the terms of the partnership, the companies will create a patient community where 23andMe customers can access regularly updated disease information and HCM research opportunities. The companies noted that more than 6,000 HCM patients are currently 23andMe customers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

More Common Than Thought

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

Even for Prizes, Women Get Less Money

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

This Week in Nature

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Scramble to Keep the Work Alive

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

Featured White Papers

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Powerful Bioinformatic Support for Specialized Therapeutic Antibody Discovery

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Main menu